文献速递基础与转化研究新药、器械与细胞基因治疗研发

少突胶质细胞来源胞外囊泡作为抗原特异性疗法治疗小鼠自身免疫性神经炎症

Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice.
PubMed 文献 · Sci Transl Med · 2020-01-01

该研究开发了少突胶质细胞来源的胞外囊泡(Ol-EVs)疗法,其天然携带多种髓鞘抗原。在多个实验性自身免疫性脑脊髓炎(EAE)模型中,静脉注射Ol-EVs以髓鞘抗原依赖的方式预防和治疗性地减轻疾病病理,且安全性良好。机制上通过诱导免疫抑制性单核细胞和自身反应性CD4+ T细胞凋亡恢复免疫耐受,人少突胶质细胞也释放含相关髓鞘抗原的EVs,为多发性硬化(MS)治疗提供了无需鉴定靶抗原的新策略。

要点

  • Ol-EVs天然携带多种髓鞘抗原,无需预先鉴定MS靶抗原即可诱导抗原特异性免疫耐受。
  • 静脉注射Ol-EVs在多个EAE模型中预防和治疗性减轻疾病,呈髓鞘抗原依赖性。
  • 机制涉及诱导免疫抑制性单核细胞和自身反应性CD4+ T细胞凋亡。

核心结论

  • 少突胶质细胞来源胞外囊泡可在不鉴定靶抗原的情况下,以髓鞘抗原特异性方式抑制中枢神经系统自身免疫。

研究设计与样本

  • 基于小鼠EAE模型(MS动物模型)的临床前治疗研究,在多个EAE模型中评估静脉注射Ol-EVs的预防和治疗效果。

主要发现

  • 静脉注射Ol-EVs在多个EAE模型中预防性和治疗性减轻疾病病理,且呈髓鞘抗原依赖性。
  • 治疗安全性良好,通过诱导免疫抑制性单核细胞和自身反应性CD4+ T细胞凋亡恢复免疫耐受。
  • 人少突胶质细胞也释放含大多数相关髓鞘抗原的胞外囊泡,为MS治疗提供基础。

临床怎么用

  • 为MS等中枢神经系统自身免疫病提供无需鉴定靶抗原的抗原特异性耐受诱导新思路。

局限性

  • 证据来自小鼠EAE模型,尚需临床研究验证人少突胶质细胞来源EVs在MS患者中的安全性与疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoimmune diseases such as multiple sclerosis (MS) develop because of failed peripheral immune tolerance for a specific self-antigen (Ag). Numerous approaches for Ag-specific suppression of autoimmune neuroinflammation have been proven effective in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. One such approach is intravenous tolerance induction by injecting a myelin Ag used for triggering EAE. However, the translation of this and similar experimental strategies into therapy for MS has been hampered by uncertainty regarding relevant myelin Ags in MS patients. To address this issue, we developed a therapeutic strategy that relies on oligodendrocyte (Ol)-derived extracellular vesicles (Ol-EVs), which naturally contain multiple myelin Ags. Intravenous Ol-EV injection reduced disease pathophysiology in a myelin Ag-dependent manner, both prophylactically and therapeutically, in several EAE models. The treatment was safe and restored immune tolerance by inducing immunosuppressive monocytes and apoptosis of autoreactive CD4+ T cells. Furthermore, we showed that human Ols also released EVs containing most relevant myelin Ags, providing a basis for their use in MS therapy. These findings introduce an approach for suppressing central nervous system (CNS) autoimmunity in a myelin Ag-specific manner, without the need to identify the target Ag.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Casella G, Rasouli J, Boehm A, et al. Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice. Sci Transl Med. 2020. PMID: 33148622. doi:10.1126/scitranslmed.aba0599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。